Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxidative stress, antioxidant depletion, and DNA damage in post-COVID-19 patients: evidence of a disrupted redox network and loss of age-dependent antioxidant compensation.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Epidemiology and Antifungal Susceptibility of Candida Bloodstream Isolates From a Tertiary Care Center in Central India.

Cureus·2025
Same author

GeneFEAST: the pivotal, gene-centric step in functional enrichment analysis interpretation.

Bioinformatics (Oxford, England)·2025
Same author

Body Mass Index a Forecast of Sputum Culture Conversion Among Drug-Resistant Tuberculosis Patients.

Cureus·2024
Same author

Molecular Identification of Non-tuberculous Mycobacteria in Suspected Tuberculosis Cases in Central India.

Cureus·2023
Same author

Assessment of the Diagnostic Utility of GeneXpert Mycobacterium tuberculosis/Rifampicin (MTB/RIF) Assay in the Suspected Cases of Tuberculous Meningitis.

Cureus·2023

Related Experiment Videos

Multi-drug resistant tuberculosis: an iatrogenic problem.

Surya Kant1, Anand K Maurya, R A S Kushwaha

  • 1Department of Pulmonary Medicine, C. S. M. Medical University UP, Lucknow, India. dr.kantskt@rediffmail.com

Bioscience Trends
|May 8, 2010
PubMed
Summary
This summary is machine-generated.

Multi-drug resistant tuberculosis (MDR-TB) poses a global health challenge. Understanding drug resistance, especially in HIV-associated cases, is crucial for developing effective treatments and control strategies.

Related Experiment Videos

Area of Science:

  • Microbiology
  • Public Health
  • Infectious Diseases

Background:

  • Drug resistance in tuberculosis (TB), particularly multi-drug resistant TB (MDR-TB), is a major global health concern.
  • MDR-TB, defined as resistance to rifampicin and isoniazid, impedes effective TB control efforts worldwide.
  • Understanding HIV-associated MDR-TB is critical for integrated treatment strategies.

Purpose of the Study:

  • To highlight the significance of understanding drug action and resistance mechanisms in TB.
  • To emphasize the need for developing novel diagnostic tools, drugs, and treatment programs for drug-resistant TB.
  • To advocate for operational field trials to evaluate management strategies like DOTS-Plus for MDR-TB.

Main Methods:

  • Literature review and synthesis of current knowledge on MDR-TB and HIV-associated TB.
  • Analysis of the impact of drug resistance on TB pathogenicity.
  • Discussion of the importance of standardized definitions and nomenclature in clinical trials.

Main Results:

  • Drug resistance, especially MDR-TB, presents a significant obstacle to global TB control.
  • Knowledge gaps in drug action and resistance hinder the development of new interventions.
  • Operational field trials are essential for validating MDR-TB management strategies.

Conclusions:

  • Addressing drug resistance in TB, particularly MDR-TB, requires a multi-faceted approach.
  • Further research into drug resistance mechanisms and pathogenicity is vital.
  • Effective global TB control necessitates robust strategies, including those for HIV-coinfected patients, validated through rigorous trials.